
    
      This study is a prospective, randomized, single-blinded, parallel, 2-treatment, multi-center
      clinical trial. A total of 224 subjects will participate to this study and be assigned to the
      test group or the control group. The subject will administer the first dose of assigned
      investigational product in the evening prior to the scheduled colonoscopy. Subject will take
      the second dose early in the morning of the colonoscopy.
    
  